

Two things-- one is, in my view at least, I've learned that PCSK9 inhibition is safe, although we still have to wait for longer exposure times. But so far, so good. Let's put it this way. And especially, it's safe with a very low level of LDL.

This is the first take-home message. The second one for these two trials is there is nothing magic about reducing LDL with one drug or another. All of them give you the benefit you would have expected, solely by the reduction of LDL.

So in other words, there is an affirmation again of the fact that statins, if they have pleiotropic effects, a so-called "pleiotropic effect," those are clinically irrelevant.